Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1981 Oct;46(1):110–119.

Hypocomplementaemia due to a genetic deficiency of beta 1H globulin.

R A Thompson, M H Winterborn
PMCID: PMC1536333  PMID: 6461451

Abstract

An 8-month-old Asian boy who presented with the haemolytic uraemic syndrome was found to have a low haemolytic complement, and in particular a very low C3 level, with a normal C4 level. These abnormalities persisted after recovery and were not associated with the presence of circulating C3 nephritic factor. A clinically healthy 3-year-old brother was found to have an identical complement profile, which indicated increased alternative pathway activation. Both brothers had normal levels of the C3b inactivator, but very low levels of beta 1H globulin (less than 10% of a reference standard serum). The parents, who were first cousins, had half-normal levels of beta 1H globulin, and low levels were found in other members of the family, indicating that the defect was inherited.

Full text

PDF
110

Images in this article

112Fig. 1
on p.112
112Fig. 2
on p.112
114Fig. 4
on p.114

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper C. A., Bloch K. J., Rosen F. S. Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3. N Engl J Med. 1973 Mar 22;288(12):601–606. doi: 10.1056/NEJM197303222881204. [DOI] [PubMed] [Google Scholar]
  2. Charlesworth J. A., Scott D. M., Pussell B. A., Peters D. K. Metabolism of human beta 1H: studies in man and experimental animals. Clin Exp Immunol. 1979 Dec;38(3):397–404. [PMC free article] [PubMed] [Google Scholar]
  3. Charlesworth J. A., Williams D. G., Sherington E., Lachmann P. J., Peters D. K. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest. 1974 Jun;53(6):1578–1587. doi: 10.1172/JCI107708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Drukker A., Winterborn M., Bennett B., Churg J., Spitzer A., Greifer I. Recurrent hemolytic-uremic syndrome: a case report. Clin Nephrol. 1975 Aug;4(2):68–72. [PubMed] [Google Scholar]
  5. Gwynn C. M., Thompson R. A. Complement changes during exercise-induced asthma. Clin Allergy. 1978 Sep;8(5):483–486. doi: 10.1111/j.1365-2222.1978.tb01500.x. [DOI] [PubMed] [Google Scholar]
  6. Jackson C. G., Ochs H. D., Wedgwood R. J. Immune response of a patient with deficiency of the fourth component of complement and systemic lupus erythematosus. N Engl J Med. 1979 May 17;300(20):1124–1129. doi: 10.1056/NEJM197905173002002. [DOI] [PubMed] [Google Scholar]
  7. Kaplan B. S., Thomson P. D., de Chadarévian J. P. The hemolytic uremic syndrome. Pediatr Clin North Am. 1976 Nov;23(4):761–777. doi: 10.1016/s0031-3955(16)33359-4. [DOI] [PubMed] [Google Scholar]
  8. NILSSON U. R., MUELLER-EBERHARD H. J. ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med. 1965 Aug 1;122:277–298. doi: 10.1084/jem.122.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Platts-Mills T. A., Ishizaka K. Activation of the alternate pathway of human complements by rabbit cells. J Immunol. 1974 Jul;113(1):348–358. [PubMed] [Google Scholar]
  10. Pussell B. A., Bourke E., Nayef M., Morris S., Peters D. K. Complement deficiency and nephritis. A report of a family. Lancet. 1980 Mar 29;1(8170):675–677. [PubMed] [Google Scholar]
  11. Seller M. J. The presence of donor-type immunoglobulins in anaemic mice of the W-series transplanted with allogeneic foetal liver cells. Immunology. 1973 Feb;24(2):249–252. [PMC free article] [PubMed] [Google Scholar]
  12. Thompson R. A. C3 inactivating factor in the serum of a patient with chronic hypocomplementaemic proliferative glomerulo-nephritis. Immunology. 1972 Jan;22(1):147–158. [PMC free article] [PubMed] [Google Scholar]
  13. Thompson R. A., Lachmann P. J. A second case of human C3b inhibitor (KAF) deficiency. Clin Exp Immunol. 1977 Jan;27(1):23–29. [PMC free article] [PubMed] [Google Scholar]
  14. Thompson R. A., Lachmann P. J. Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med. 1970 Apr 1;131(4):629–641. doi: 10.1084/jem.131.4.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Thompson R. A. Measurement of functional C2--a method for clinical laboratories. J Immunol Methods. 1978;24(3-4):223–227. doi: 10.1016/0022-1759(78)90126-6. [DOI] [PubMed] [Google Scholar]
  16. Whaley K., Ruddy S. Modulation of C3b hemolytic activity by a plasma protein distinct from C3b inactivator. Science. 1976 Sep 10;193(4257):1011–1013. doi: 10.1126/science.948757. [DOI] [PubMed] [Google Scholar]
  17. Whaley K., Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med. 1976 Nov 2;144(5):1147–1163. doi: 10.1084/jem.144.5.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Whaley K., Thompson R. A. Requirements for beta1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum. Immunology. 1978 Dec;35(6):1045–1049. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES